Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Cancer and Metastasis Reviews
Erschienen in: Cancer and Metastasis Reviews 2-3/2014

01.09.2014

The role of epithelial plasticity in prostate cancer dissemination and treatment resistance

verfasst von: Rhonda L. Bitting, Daneen Schaeffer, Jason A. Somarelli, Mariano A. Garcia-Blanco, Andrew J. Armstrong

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 2-3/2014

Einloggen, um Zugang zu erhalten

Abstract

Nearly 30,000 men die annually in the USA of prostate cancer, nearly uniformly from metastatic dissemination. Despite recent advances in hormonal, immunologic, bone-targeted, and cytotoxic chemotherapies, treatment resistance and further dissemination are inevitable in men with metastatic disease. Emerging data suggests that the phenomenon of epithelial plasticity, encompassing both reversible mesenchymal transitions and acquisition of stemness traits, may underlie this lethal biology of dissemination and treatment resistance. Understanding the molecular underpinnings of this cellular plasticity from preclinical models of prostate cancer and from biomarker studies of human metastatic prostate cancer has provided clues to novel therapeutic approaches that may delay or prevent metastatic disease and lethality over time. This review will discuss the preclinical and clinical evidence for epithelial plasticity in this rapidly changing field and relate this to clinical phenotype and resistance in prostate cancer while suggesting novel therapeutic approaches.
Literatur
1.
Siegel, R., Naishadham, D., & Jemal, A. (2012). Cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 62, 10–29.
2.
Rini, B. I., & Small, E. J. (2002). Hormone-refractory prostate cancer. Current Treatment Options in Oncology, 3, 437–446.PubMed
3.
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004). Molecular determinants of resistance to antiandrogen therapy. Nature Medicine, 10, 33–39.PubMed
4.
Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L., & Tindall, D. J. (2008). Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Research, 68, 5469–5477.PubMedCentralPubMed
5.
Mostaghel, E. A., Page, S. T., Lin, D. W., Fazli, L., Coleman, I. M., True, L. D., Knudsen, B., Hess, D. L., Nelson, C. C., Matsumoto, A. M., Bremner, W. J., Gleave, M. E., & Nelson, P. S. (2007). Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Research, 67, 5033–5041.PubMed
6.
Shah, R. B., Mehra, R., Chinnaiyan, A. M., Shen, R., Ghosh, D., Zhou, M., Macvicar, G. R., Varambally, S., Harwood, J., Bismar, T. A., Kim, R., Rubin, M. A., & Pienta, K. J. (2004). Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program. Cancer Research, 64, 9209–9216.PubMed
7.
Rubin, M. A., Putzi, M., Mucci, N., Smith, D. C., Wojno, K., Korenchuk, S., & Pienta, K. J. (2000). Rapid (“warm”) autopsy study for procurement of metastatic prostate cancer. Clinical Cancer Research, 6, 1038–1045.PubMed
8.
Liu, W., Laitinen, S., Khan, S., Vihinen, M., Kowalski, J., Yu, G., Chen, L., Ewing, C. M., Eisenberger, M. A., Carducci, M. A., Nelson, W. G., Yegnasubramanian, S., Luo, J., Wang, Y., Xu, J., Isaacs, W. B., Visakorpi, T., & Bova, G. S. (2009). Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nature Medicine, 15, 559–565.PubMedCentralPubMed
9.
Aryee, M. J., Liu, W., Engelmann, J. C., Nuhn, P., Gurel, M., Haffner, M. C., Esopi, D., Irizarry, R. A., Getzenberg, R. H., Nelson, W. G., Luo, J., Xu, J., Isaacs, W. B., Bova, G. S., & Yegnasubramanian, S. (2013). “DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases,”. Science Translational Medicine, 5, 169ra10.PubMedCentralPubMed
10.
Mani, S. A., Guo, W., Liao, M. J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., Campbell, L. L., Polyak, K., Brisken, C., Yang, J., & Weinberg, R. A. (2008). The epithelial–mesenchymal transition generates cells with properties of stem cells. Cell, 133, 704–715.PubMedCentralPubMed
11.
Thiery, J. P., & Sleeman, J. P. (2006). Complex networks orchestrate epithelial–mesenchymal transitions. Nature Reviews Molecular Cell Biology, 7, 131–142.PubMed
12.
Blick, T., Widodo, E., Hugo, H., Waltham, M., Lenburg, M. E., Neve, R. M., & Thompson, E. W. (2008). Epithelial mesenchymal transition traits in human breast cancer cell lines. Clinical & Experimental Metastasis, 25, 629–642.
13.
Hugo, H., Ackland, M. L., Blick, T., Lawrence, M. G., Clements, J. A., Williams, E. D., & Thompson, E. W. (2007). Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. Journal of Cellular Physiology, 213, 374–383.PubMed
14.
Giannoni, E., Bianchini, F., Masieri, L., Serni, S., Torre, E., Calorini, L., & Chiarugi, P. (2010). Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial–mesenchymal transition and cancer stemness. Cancer Research, 70, 6945–6956.PubMed
15.
Armstrong, A. J., Marengo, M. S., Oltean, S., Kemeny, G., Bitting, R. L., Turnbull, J. D., Herold, C. I., Marcom, P. K., George, D. J., & Garcia-Blanco, M. A. (2011). Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Molecular Cancer Research, 9, 997–1007.PubMedCentralPubMed
16.
Zhu, M. L., & Kyprianou, N. (2010). Role of androgens and the androgen receptor in epithelial–mesenchymal transition and invasion of prostate cancer cells. FASEB Journal, 24, 769–777.PubMedCentralPubMed
17.
Li, X., Lewis, M. T., Huang, J., Gutierrez, C., Osborne, C. K., Wu, M. F., Hilsenbeck, S. G., Pavlick, A., Zhang, X., Chamness, G. C., Wong, H., Rosen, J., & Chang, J. C. (2008). Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. Journal of the National Cancer Institute, 100, 672–679.PubMed
18.
Abraham, B. K., Fritz, P., McClellan, M., Hauptvogel, P., Athelogou, M., & Brauch, H. (2005). Prevalence of CD44+/CD24−/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clinical Cancer Research, 11, 1154–1159.PubMed
19.
Ginestier, C., Hur, M. H., Charafe-Jauffret, E., Monville, F., Dutcher, J., Brown, M., Jacquemier, J., Viens, P., Kleer, C. G., Liu, S., Schott, A., Hayes, D., Birnbaum, D., Wicha, M. S., & Dontu, G. (2007). ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 1, 555–567.PubMedCentralPubMed
20.
Taplin, M. E., George, D. J., Halabi, S., Sanford, B., Febbo, P. G., Hennessy, K. T., Mihos, C. G., Vogelzang, N. J., Small, E. J., & Kantoff, P. W. (2005). Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology, 66, 386–391.PubMed
21.
Aparicio, A. M., Harzstark, A., Corn, P. G., Wen, S., Araujo, J., Tu, S. M., Pagliaro, L., Kim, J., Millikan, R. E., Ryan, C. J., Tannir, N. M., Zurita, A., Mathew, P., Arap, W., Troncoso, P., Thall, P., & Logothetis, C. J. (2013). Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res, 19, 3621–3630.PubMedCentralPubMed
22.
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., Akhavanfard, S., Heist, R. S., Temel, J., Christensen, J. G., Wain, J. C., Lynch, T. J., Vernovsky, K., Mark, E. J., Lanuti, M., Iafrate, A. J., Mino-Kenudson, M., & Engelman, J. A. (2011). Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Science Translational Medicine, 3, 75ra26.PubMedCentralPubMed
23.
Parwani, A. V., Kronz, J. D., Genega, E. M., Gaudin, P., Chang, S., & Epstein, J. I. (2004). Prostate carcinoma with squamous differentiation: An analysis of 33 cases. The American Journal of Surgical Pathology, 28, 651–657.PubMed
24.
di Sant’Agnese, P. A. (2001). Neuroendocrine differentiation in prostatic carcinoma: An update on recent developments. Annals of Oncology, 12(Suppl 2), S135–S140.PubMed
25.
Berruti, A., Mosca, A., Tucci, M., Terrone, C., Torta, M., Tarabuzzi, R., Russo, L., Cracco, C., Bollito, E., Scarpa, R. M., Angeli, A., & Dogliotti, L. (2005). Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocrine-Related Cancer, 12, 109–117.PubMed
26.
Wang, W., & Epstein, J. I. (2008). Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. The American Journal of Surgical Pathology, 32, 65–71.PubMed
27.
Kalluri, R., & Weinberg, R. A. (2009). The basics of epithelial–mesenchymal transition. Journal of Clinical Investigation, 119, 1420–1428.PubMedCentralPubMed
28.
Beltran, H., Rickman, D. S., Park, K., Chae, S. S., Sboner, A., MacDonald, T. Y., Wang, Y., Sheikh, K. L., Terry, S., Tagawa, S. T., Dhir, R., Nelson, J. B., de la Taille, A., Allory, Y., Gerstein, M. B., Perner, S., Pienta, K. J., Chinnaiyan, A. M., Collins, C. C., Gleave, M. E., Demichelis, F., Nanus, D. M., & Rubin, M. A. (2011). Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discovery, 1, 487–495.PubMedCentralPubMed
29.
Giannoni, E., Taddei, M. L., Parri, M., Bianchini, F., Santosuosso, M., Grifantini, R., Fibbi, G., Mazzanti, B., Calorini, L., & Chiarugi, P. (2013). EphA2-mediated mesenchymal-amoeboid transition induced by endothelial progenitor cells enhances metastatic spread due to cancer-associated fibroblasts. Journal Molecules Medical (Berl), 91, 103–115.
30.
Koeneman, K. S., Yeung, F., & Chung, L. W. (1999). Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate, 39, 246–261.PubMed
31.
Josson, S., Nomura, T., Lin, J. T., Huang, W. C., Wu, D., Zhau, H. E., Zayzafoon, M., Weizmann, M. N., Gururajan, M., & Chung, L. W. (2011). beta2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Research, 71, 2600–2610.PubMedCentralPubMed
32.
Zhau, H. E., He, H., Wang, C. Y., Zayzafoon, M., Morrissey, C., Vessella, R. L., Marshall, F. F., Chung, L. W., & Wang, R. (2011). Human prostate cancer harbors the stem cell properties of bone marrow mesenchymal stem cells. Clinical Cancer Research, 17, 2159–2169.PubMedCentralPubMed
33.
Yang, J., Fizazi, K., Peleg, S., Sikes, C. R., Raymond, A. K., Jamal, N., Hu, M., Olive, M., Martinez, L. A., Wood, C. G., Logothetis, C. J., Karsenty, G., & Navone, N. M. (2001). Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Research, 61, 5652–5659.PubMed
34.
Zhau, H. Y., Chang, S. M., Chen, B. Q., Wang, Y., Zhang, H., Kao, C., Sang, Q. A., Pathak, S. J., & Chung, L. W. (1996). Androgen-repressed phenotype in human prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 93, 15152–15157.PubMedCentralPubMed
35.
Ke, X. S., Qu, Y., Goldfinger, N., Rostad, K., Hovland, R., Akslen, L. A., Rotter, V., Oyan, A. M., & Kalland, K. H. (2008). Epithelial to mesenchymal transition of a primary prostate cell line with switches of cell adhesion modules but without malignant transformation. PLoS One, 3, e3368.PubMedCentralPubMed
36.
Marian, C. O., Yang, L., Zou, Y. S., Gore, C., Pong, R. C., Shay, J. W., Kabbani, W., Hsieh, J. T., & Raj, G. V. (2011). Evidence of epithelial to mesenchymal transition associated with increased tumorigenic potential in an immortalized normal prostate epithelial cell line. Prostate, 71, 626–636.PubMed
37.
Celia-Terrassa, T., Meca-Cortes, O., Mateo, F., de Paz, A. M., Rubio, N., Arnal-Estape, A., Ell, B. J., Bermudo, R., Diaz, A., Guerra-Rebollo, M., Lozano, J. J., Estaras, C., Ulloa, C., Alvarez-Simon, D., Mila, J., Vilella, R., Paciucci, R., Martinez-Balbas, M., de Herreros, A. G., Gomis, R. R., Kang, Y., Blanco, J., Fernandez, P. L., & Thomson, T. M. (2012). Epithelial–mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. The Journal of Clinical Investigation, 122, 1849–1868.PubMedCentralPubMed
38.
Moody, S. E., Perez, D., Pan, T. C., Sarkisian, C. J., Portocarrero, C. P., Sterner, C. J., Notorfrancesco, K. L., Cardiff, R. D., & Chodosh, L. A. (2005). The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell, 8, 197–209.PubMed
39.
Fan, F., Samuel, S., Evans, K. W., Lu, J., Xia, L., Zhou, Y., Sceusi, E., Tozzi, F., Ye, X. C., Mani, S. A., & Ellis, L. M. (2012). Overexpression of Snail induces epithelial–mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells. Cancer Medical, 1, 5–16.
40.
Emadi Baygi, M., Soheili, Z. S., Schmitz, I., Sameie, S., & Schulz, W. A. (2010). Snail regulates cell survival and inhibits cellular senescence in human metastatic prostate cancer cell lines. Cell Biology and Toxicology, 26, 553–567.PubMed
41.
McKeithen, D., Graham, T., Chung, L. W., & Odero-Marah, V. (2010). Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cells. Prostate, 70, 982–992.PubMedCentralPubMed
42.
Emadi Baygi, M., Soheili, Z. S., Essmann, F., Deezagi, A., Engers, R., Goering, W., & Schulz, W. A. (2010). Slug/SNAI2 regulates cell proliferation and invasiveness of metastatic prostate cancer cell lines. Tumour Biology, 31, 297–307.PubMed
43.
Wu, K., Gore, C., Yang, L., Fazli, L., Gleave, M., Pong, R. C., Xiao, G., Zhang, L., Yun, E. J., Tseng, S. F., Kapur, P., He, D., & Hsieh, J. T. (2012). Slug, a unique androgen-regulated transcription factor, coordinates androgen receptor to facilitate castration resistance in prostate cancer. Molecular Endocrinology, 26, 1496–1507.PubMed
44.
Graham, T. R., Zhau, H. E., Odero-Marah, V. A., Osunkoya, A. O., Kimbro, K. S., Tighiouart, M., Liu, T., Simons, J. W., & O’Regan, R. M. (2008). Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Research, 68, 2479–2488.PubMed
45.
Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R. A., Come, C., Savagner, P., Gitelman, I., Richardson, A., & Weinberg, R. A. (2004). Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell, 117, 927–939.PubMed
46.
Liu, A. N., Zhu, Z. H., Chang, S. J., & Hang, X. S. (2012). Twist expression associated with the epithelial–mesenchymal transition in gastric cancer. Molecular and Cellular Biochemistry, 367, 195–203.PubMed
47.
Yang, M. H., Hsu, D. S., Wang, H. W., Wang, H. J., Lan, H. Y., Yang, W. H., Huang, C. H., Kao, S. Y., Tzeng, C. H., Tai, S. K., Chang, S. Y., Lee, O. K., & Wu, K. J. (2010). Bmi1 is essential in Twist1-induced epithelial–mesenchymal transition. Nature Cell Biology, 12, 982–992.PubMed
48.
Eckert, M. A., Lwin, T. M., Chang, A. T., Kim, J., Danis, E., Ohno-Machado, L., & Yang, J. (2011). Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell, 19, 372–386.PubMedCentralPubMed
49.
Peinado, H., Olmeda, D., & Cano, A. (2007). Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype? Nature Reviews Cancer, 7, 415–428.PubMed
50.
Watson, M. A., Ylagan, L. R., Trinkaus, K. M., Gillanders, W. E., Naughton, M. J., Weilbaecher, K. N., Fleming, T. P., & Aft, R. L. (2007). Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients. Clinical Cancer Research, 13, 5001–5009.PubMedCentralPubMed
51.
Alexander, N. R., Tran, N. L., Rekapally, H., Summers, C. E., Glackin, C., & Heimark, R. L. (2006). N-Cadherin gene expression in prostate carcinoma is modulated by integrin-dependent nuclear translocation of Twist1. Cancer Research, 66, 3365–3369.PubMed
52.
Fridman, J. S., & Lowe, S. W. (2003). Control of apoptosis by p53. Oncogene, 22, 9030–9040.PubMed
53.
Vousden, K. H. (2000). p53: Death star. Cell, 103, 691–694.PubMed
54.
Sigal, A., & Rotter, V. (2000). Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Research, 60, 6788–6793.PubMed
55.
Chang, C. J., Chao, C. H., Xia, W., Yang, J. Y., Xiong, Y., Li, C. W., Yu, W. H., Rehman, S. K., Hsu, J. L., Lee, H. H., Liu, M., Chen, C. T., Yu, D., & Hung, M. C. (2011). p53 regulates epithelial–mesenchymal transition and stem cell properties through modulating miRNAs. Nature Cell Biology, 13, 317–323.PubMedCentralPubMed
56.
Perk, J., Iavarone, A., & Benezra, R. (2005). Id family of helix–loop–helix proteins in cancer. Nature Reviews Cancer, 5, 603–614.PubMed
57.
Ouyang, X. S., Wang, X., Lee, D. T., Tsao, S. W., & Wong, Y. C. (2002). Over expression of ID-1 in prostate cancer. The Journal of Urology, 167, 2598–2602.PubMed
58.
Zhang, X., Ling, M. T., Wang, Q., Lau, C. K., Leung, S. C., Lee, T. K., Cheung, A. L., Wong, Y. C., & Wang, X. (2007). Identification of a novel inhibitor of differentiation-1 (ID-1) binding partner, caveolin-1, and its role in epithelial–mesenchymal transition and resistance to apoptosis in prostate cancer cells. The Journal of Biological Chemistry, 282, 33284–33294.PubMed
59.
Williams, T. M., & Lisanti, M. P. (2005). Caveolin-1 in oncogenic transformation, cancer, and metastasis. American Journal of Physiology. Cell Physiology, 288, C494–C506.PubMed
60.
Yang, G., Truong, L. D., Wheeler, T. M., & Thompson, T. C. (1999). Caveolin-1 expression in clinically confined human prostate cancer: A novel prognostic marker. Cancer Research, 59, 5719–5723.PubMed
61.
Li, L., Ren, C. H., Tahir, S. A., Ren, C., & Thompson, T. C. (2003). Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Molecular and Cellular Biology, 23, 9389–9404.PubMedCentralPubMed
62.
Wu, C., & Huang, J. (2007). Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer. The Journal of Biological Chemistry, 282, 3571–3583.PubMed
63.
Ciarlo, M., Benelli, R., Barbieri, O., Minghelli, S., Barboro, P., Balbi, C., & Ferrari, N. (2012). Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/beta-catenin signaling in prostate cancer cells. International Journal of Cancer, 131, 582–590.
64.
Murthy, S., Wu, M., Bai, V. U., Hou, Z., Menon, M., Barrack, E. R., Kim, S. H., & Reddy, G. P. (2013). Role of androgen receptor in progression of LNCaP prostate cancer cells from G1 to S phase. PLoS One, 8, e56692.PubMedCentralPubMed
65.
Sun, Y., Wang, B. E., Leong, K. G., Yue, P., Li, L., Jhunjhunwala, S., Chen, D., Seo, K., Modrusan, Z., Gao, W. Q., Settleman, J., & Johnson, L. (2012). Androgen deprivation causes epithelial–mesenchymal transition in the prostate: Implications for androgen-deprivation therapy. Cancer Research, 72, 527–536.PubMed
66.
Eide, T., Ramberg, H., Glackin, C., Tindall, D., & Tasken, K. A. (2013). TWIST1, A novel androgen-regulated gene, is a target for NKX3-1 in prostate cancer cells. Cancer Cell International, 13, 4.PubMedCentralPubMed
67.
Lu, T., Lin, W. J., Izumi, K., Wang, X., Xu, D., Fang, L. Y., Li, L., Jiang, Q., Jin, J., & Chang, C. (2012). Targeting androgen receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development. Molecular Endocrinology, 26, 1707–1715.PubMedCentralPubMed
68.
Pourmand, G., Ziaee, A. A., Abedi, A. R., Mehrsai, A., Alavi, H. A., Ahmadi, A., & Saadati, H. R. (2007). Role of PTEN gene in progression of prostate cancer. Urology Journal, 4, 95–100. Spring.PubMed
69.
Mulholland, D. J., Kobayashi, N., Ruscetti, M., Zhi, A., Tran, L. M., Huang, J., Gleave, M., & Wu, H. (2012). Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Research, 72, 1878–1889.PubMedCentralPubMed
70.
Dubrovska, A., Kim, S., Salamone, R. J., Walker, J. R., Maira, S. M., Garcia-Echeverria, C., Schultz, P. G., & Reddy, V. A. (2009). The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proceedings of the National Academy of Sciences of the United States of America, 106, 268–273.PubMedCentralPubMed
71.
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., Antipin, Y., Mitsiades, N., Landers, T., Dolgalev, I., Major, J. E., Wilson, M., Socci, N. D., Lash, A. E., Heguy, A., Eastham, J. A., Scher, H. I., Reuter, V. E., Scardino, P. T., Sander, C., Sawyers, C. L., & Gerald, W. L. (2010). Integrative genomic profiling of human prostate cancer. Cancer Cell, 18, 11–22.PubMedCentralPubMed
72.
Nusse, R., & Varmus, H. (2012). Three decades of Wnts: A personal perspective on how a scientific field developed. EMBO Journal, 31, 2670–2684.PubMedCentralPubMed
73.
Yee, D. S., Tang, Y., Li, X., Liu, Z., Guo, Y., Ghaffar, S., McQueen, P., Atreya, D., Xie, J., Simoneau, A. R., Hoang, B. H., & Zi, X. (2010). The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. Molecular Cancer, 9, 162.PubMedCentralPubMed
74.
Clevers, H. (2006). Wnt/beta-catenin signaling in development and disease. Cell, 127, 469–480.PubMed
75.
Truica, C. I., Byers, S., & Gelmann, E. P. (2000). Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Research, 60, 4709–4713.PubMed
76.
Whitaker, H. C., Girling, J., Warren, A. Y., Leung, H., Mills, I. G., & Neal, D. E. (2008). Alterations in beta-catenin expression and localization in prostate cancer. Prostate, 68, 1196–1205.PubMed
77.
Wan, X., Liu, J., Lu, J. F., Tzelepi, V., Yang, J., Starbuck, M. W., Diao, L., Wang, J., Efstathiou, E., Vazquez, E. S., Troncoso, P., Maity, S. N., & Navone, N. M. (2012). Activation of beta-catenin signaling in androgen receptor-negative prostate cancer cells. Clinical Cancer Research, 18, 726–736.PubMedCentralPubMed
78.
Cao, J., Chiarelli, C., Richman, O., Zarrabi, K., Kozarekar, P., & Zucker, S. (2008). Membrane type 1 matrix metalloproteinase induces epithelial-to-mesenchymal transition in prostate cancer. The Journal of Biological Chemistry, 283, 6232–6240.PubMed
79.
Xie, D., Gore, C., Liu, J., Pong, R. C., Mason, R., Hao, G., Long, M., Kabbani, W., Yu, L., Zhang, H., Chen, H., Sun, X., Boothman, D. A., Min, W., & Hsieh, J. T. (2010). “Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis,“. Proceedings of the National Academy of Sciences of the United States of America, 107, 2485–2490.PubMedCentralPubMed
80.
Min, J., Zaslavsky, A., Fedele, G., McLaughlin, S. K., Reczek, E. E., De Raedt, T., Guney, I., Strochlic, D. E., Macconaill, L. E., Beroukhim, R., Bronson, R. T., Ryeom, S., Hahn, W. C., Loda, M., & Cichowski, K. (2010). ”An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nature Medicine, 16, 286–294.PubMedCentralPubMed
81.
K. Wu, J. Liu, S. F. Tseng, C. Gore, Z. Ning, N. Sharifi, L. Fazli, M. Gleave, P. Kapur, G. Xiao, X. Sun, O. K. Oz, W. Min, G. Alexandrakis, C. R. Yang, C. L. Hsieh, H. C. Wu, D. He, D. Xie, and J. T. Hsieh,”The role of DAB2IP in androgen receptor activation during prostate cancer progression,“Oncogene, Apr 22 2013.
82.
Jain, G., Cronauer, M. V., Schrader, M., Moller, P., & Marienfeld, R. B. (2012). NF-kappaB signaling in prostate cancer: a promising therapeutic target? World Journal of Urology, 30, 303–310.PubMed
83.
McCall, P., Bennett, L., Ahmad, I., Mackenzie, L. M., Forbes, I. W., Leung, H. Y., Sansom, O. J., Orange, C., Seywright, M., Underwood, M. A., & Edwards, J. (2012). NFkappaB signalling is upregulated in a subset of castrate-resistant prostate cancer patients and correlates with disease progression. British Journal of Cancer, 107, 1554–1563.PubMedCentralPubMed
84.
Min, C., Eddy, S. F., Sherr, D. H., & Sonenshein, G. E. (2008). NF-kappaB and epithelial to mesenchymal transition of cancer. Journal of Cellular Biochemistry, 104, 733–744.PubMed
85.
Luo, J. L., Tan, W., Ricono, J. M., Korchynskyi, O., Zhang, M., Gonias, S. L., Cheresh, D. A., & Karin, M. (2007). Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature, 446, 690–694.PubMed
86.
Odero-Marah, V. A., Wang, R., Chu, G., Zayzafoon, M., Xu, J., Shi, C., Marshall, F. F., Zhau, H. E., & Chung, L. W. (2008). Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Research, 18, 858–870.PubMed
87.
Kuo, P. L., Shen, K. H., Hung, S. H., & Hsu, Y. L. (2012). CXCL1/GROalpha increases cell migration and invasion of prostate cancer by decreasing fibulin-1 expression through NF-kappaB/HDAC1 epigenetic regulation. Carcinogenesis, 33, 2477–2487.PubMed
88.
Bolitho, C., Hahn, M. A., Baxter, R. C., & Marsh, D. J. (2010). The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor. Endocrine-Related Cancer, 17, 929–940.PubMed
89.
Shiota, M., Zardan, A., Takeuchi, A., Kumano, M., Beraldi, E., Naito, S., Zoubeidi, A., & Gleave, M. E. (2012). Clusterin mediates TGF-beta-induced epithelial–mesenchymal transition and metastasis via Twist1 in prostate cancer cells. Cancer Research, 72, 5261–5272.PubMed
90.
Mak, P., Leav, I., Pursell, B., Bae, D., Yang, X., Taglienti, C. A., Gouvin, L. M., Sharma, V. M., & Mercurio, A. M. (2010). ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell, 17, 319–332.PubMedCentralPubMed
91.
Poon, S., Easterbrook-Smith, S. B., Rybchyn, M. S., Carver, J. A., & Wilson, M. R. (2000). Clusterin is an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed proteins in a folding-competent state. Biochemistry, 39, 15953–15960.PubMed
92.
Chi, K. N., Hotte, S. J., Yu, E. Y., Tu, D., Eigl, B. J., Tannock, I., Saad, F., North, S., Powers, J., Gleave, M. E., & Eisenhauer, E. A. (2010). Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, 28, 4247–4254.PubMed
93.
Zoubeidi, A., Chi, K., & Gleave, M. (2010). Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clinical Cancer Research, 16, 1088–1093.PubMedCentralPubMed
94.
Turley, R. S., Finger, E. C., Hempel, N., How, T., Fields, T. A., & Blobe, G. C. (2007). The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Research, 67, 1090–1098.PubMed
95.
Ikushima, H., & Miyazono, K. (2010). TGFbeta signalling: a complex web in cancer progression. Nature Reviews Cancer, 10, 415–424.PubMed
96.
Adorno, M., Cordenonsi, M., Montagner, M., Dupont, S., Wong, C., Hann, B., Solari, A., Bobisse, S., Rondina, M. B., Guzzardo, V., Parenti, A. R., Rosato, A., Bicciato, S., Balmain, A., & Piccolo, S. (2009). A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell, 137, 87–98.PubMed
97.
Ding, Z., Wu, C. J., Chu, G. C., Xiao, Y., Ho, D., Zhang, J., Perry, S. R., Labrot, E. S., Wu, X., Lis, R., Hoshida, Y., Hiller, D., Hu, B., Jiang, S., Zheng, H., Stegh, A. H., Scott, K. L., Signoretti, S., Bardeesy, N., Wang, Y. A., Hill, D. E., Golub, T. R., Stampfer, M. J., Wong, W. H., Loda, M., Mucci, L., Chin, L., & DePinho, R. A. (2011). SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature, 470, 269–273.PubMedCentralPubMed
98.
Qin, J., Wu, S. P., Creighton, C. J., Dai, F., Xie, X., Cheng, C. M., Frolov, A., Ayala, G., Lin, X., Feng, X. H., Ittmann, M. M., Tsai, S. J., Tsai, M. J., & Tsai, S. Y. (2013). COUP-TFII inhibits TGF-beta-induced growth barrier to promote prostate tumorigenesis. Nature, 493, 236–240.PubMedCentralPubMed
99.
Buijs, J. T., Henriquez, N. V., van Overveld, P. G., van der Horst, G., ten Dijke, P., & van der Pluijm, G. (2007). TGF-beta and BMP7 interactions in tumour progression and bone metastasis. Clinical & Experimental Metastasis, 24, 609–617.
100.
Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G. Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., & Karin, M. (2009). IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell, 15, 103–113.PubMedCentralPubMed
101.
Bollrath, J., Phesse, T. J., von Burstin, V. A., Putoczki, T., Bennecke, M., Bateman, T., Nebelsiek, T., Lundgren-May, T., Canli, O., Schwitalla, S., Matthews, V., Schmid, R. M., Kirchner, T., Arkan, M. C., Ernst, M., & Greten, F. R. (2009). gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell, 15, 91–102.PubMed
102.
Yadav, A., Kumar, B., Datta, J., Teknos, T. N., & Kumar, P. (2011). IL-6 promotes head and neck tumor metastasis by inducing epithelial–mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Molecular Cancer Research, 9, 1658–1667.PubMedCentralPubMed
103.
Yao, Z., Fenoglio, S., Gao, D. C., Camiolo, M., Stiles, B., Lindsted, T., Schlederer, M., Johns, C., Altorki, N., Mittal, V., Kenner, L., & Sordella, R. (2010). TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 107, 15535–15540.PubMedCentralPubMed
104.
Sullivan, N. J., Sasser, A. K., Axel, A. E., Vesuna, F., Raman, V., Ramirez, N., Oberyszyn, T. M., & Hall, B. M. (2009). Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells. Oncogene, 28, 2940–2947.PubMed
105.
Tenniswood, M. P., Guenette, R. S., Lakins, J., Mooibroek, M., Wong, P., & Welsh, J. E. (1992). Active cell death in hormone-dependent tissues. Cancer Metastasis Reviews, 11, 197–220.PubMed
106.
Paul, C., Manero, F., Gonin, S., Kretz-Remy, C., Virot, S., & Arrigo, A. P. (2002). Hsp27 as a negative regulator of cytochrome C release. Molecular and Cellular Biology, 22, 816–834.PubMedCentralPubMed
107.
Zoubeidi, A., & Gleave, M. (2012). Small heat shock proteins in cancer therapy and prognosis. The International Journal of Biochemistry & Cell Biology, 44, 1646–1656.
108.
Shiota, M., Bishop, J. L., Nip, K. M., Zardan, A., Takeuchi, A., Cordonnier, T., Beraldi, E., Bazov, J., Fazli, L., Chi, K., Gleave, M., & Zoubeidi, A. (2013). Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. Cancer Research, 73, 3109–3119.PubMed
109.
Lue, H. W., Yang, X., Wang, R., Qian, W., Xu, R. Z., Lyles, R., Osunkoya, A. O., Zhou, B. P., Vessella, R. L., Zayzafoon, M., Liu, Z. R., Zhau, H. E., & Chung, L. W. (2011). LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling. PLoS One, 6, e27720.PubMedCentralPubMed
110.
Mimeault, M., & Batra, S. K. (2010). Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. Journal of Cellular Physiology, 224, 626–635.PubMedCentralPubMed
111.
Cheung, P. K., Woolcock, B., Adomat, H., Sutcliffe, M., Bainbridge, T. C., Jones, E. C., Webber, D., Kinahan, T., Sadar, M., Gleave, M. E., & Vielkind, J. (2004). Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis. Cancer Research, 64, 5929–5933.PubMed
112.
Nakamura, T., Scorilas, A., Stephan, C., Yousef, G. M., Kristiansen, G., Jung, K., & Diamandis, E. P. (2003). Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. British Journal of Cancer, 88, 1101–1104.PubMedCentralPubMed
113.
Veveris-Lowe, T. L., Lawrence, M. G., Collard, R. L., Bui, L., Herington, A. C., Nicol, D. L., & Clements, J. A. (2005). Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial–mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocrine-Related Cancer, 12, 631–643.PubMed
114.
Jang, M. J., Baek, S. H., & Kim, J. H. (2011). UCH-L1 promotes cancer metastasis in prostate cancer cells through EMT induction. Cancer Letters, 302, 128–135.PubMed
115.
Wesche, J., Haglund, K., & Haugsten, E. M. (2011). Fibroblast growth factors and their receptors in cancer. The Biochemical Journal, 437, 199–213.PubMed
116.
Feng, S., Wang, F., Matsubara, A., Kan, M., & McKeehan, W. L. (1997). Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. Cancer Research, 57, 5369–5378.PubMed
117.
Kwabi-Addo, B., Ropiquet, F., Giri, D., & Ittmann, M. (2001). Alternative splicing of fibroblast growth factor receptors in human prostate cancer. Prostate, 46, 163–172.PubMed
118.
Carstens, R. P., Wagner, E. J., & Garcia-Blanco, M. A. (2000). An intronic splicing silencer causes skipping of the IIIb exon of fibroblast growth factor receptor 2 through involvement of polypyrimidine tract binding protein. Molecular and Cellular Biology, 20, 7388–7400.PubMedCentralPubMed
119.
Baraniak, A. P., Chen, J. R., & Garcia-Blanco, M. A. (2006). Fox-2 mediates epithelial cell-specific fibroblast growth factor receptor 2 exon choice. Molecular and Cellular Biology, 26, 1209–1222.PubMedCentralPubMed
120.
Warzecha, C. C., Sato, T. K., Nabet, B., Hogenesch, J. B., & Carstens, R. P. (2009). ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Molecular Cell, 33, 591–601.PubMedCentralPubMed
121.
Shapiro, I. M., Cheng, A. W., Flytzanis, N. C., Balsamo, M., Condeelis, J. S., Oktay, M. H., Burge, C. B., & Gertler, F. B. (2011). An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genetics, 7, e1002218.PubMedCentralPubMed
122.
Acevedo, V. D., Gangula, R. D., Freeman, K. W., Li, R., Zhang, Y., Wang, F., Ayala, G. E., Peterson, L. E., Ittmann, M., & Spencer, D. M. (2007). Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell, 12, 559–571.PubMed
123.
Bao, B., Ahmad, A., Kong, D., Ali, S., Azmi, A. S., Li, Y., Banerjee, S., Padhye, S., & Sarkar, F. H. (2012). Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. PLoS One, 7, e43726.PubMedCentralPubMed
124.
Wang, G. L., & Semenza, G. L. (1993). General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proceedings of the National Academy of Sciences of the United States of America, 90, 4304–4308.PubMedCentralPubMed
125.
Zhao, J. H., Luo, Y., Jiang, Y. G., He, D. L., & Wu, C. T. (2011). Knockdown of beta-catenin through shRNA cause a reversal of EMT and metastatic phenotypes induced by HIF-1alpha. Cancer Investigation, 29, 377–382.PubMed
126.
Luo, Y., He, D. L., Ning, L., Shen, S. L., Li, L., & Li, X. (2006). Hypoxia-inducible factor-1alpha induces the epithelial–mesenchymal transition of human prostatecancer cells. Chinese Medical Journal, 119, 713–718.PubMed
127.
Yang, M. H., Wu, M. Z., Chiou, S. H., Chen, P. M., Chang, S. Y., Liu, C. J., Teng, S. C., & Wu, K. J. (2008). Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nature Cell Biology, 10, 295–305.PubMed
128.
Sun, S., Ning, X., Zhang, Y., Lu, Y., Nie, Y., Han, S., Liu, L., Du, R., Xia, L., He, L., & Fan, D. (2009). Hypoxia-inducible factor-1alpha induces Twist expression in tubular epithelial cells subjected to hypoxia, leading to epithelial-to-mesenchymal transition. Kidney International, 75, 1278–1287.PubMed
129.
Song, X., Wang, H., Logsdon, C. D., Rashid, A., Fleming, J. B., Abbruzzese, J. L., Gomez, H. F., & Evans, D. B. (2011). Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer, 117, 734–743.PubMed
130.
Mudduluru, G., Vajkoczy, P., & Allgayer, H. (2010). Myeloid zinc finger 1 induces migration, invasion, and in vivo metastasis through Axl gene expression in solid cancer. Molecular Cancer Research, 8, 159–169.PubMed
131.
Gustafsson, A., Bostrom, A. K., Ljungberg, B., Axelson, H., & Dahlback, B. (2009). Gas6 and the receptor tyrosine kinase Axl in clear cell renal cell carcinoma. PLoS One, 4, e7575.PubMedCentralPubMed
132.
Gjerdrum, C., Tiron, C., Hoiby, T., Stefansson, I., Haugen, H., Sandal, T., Collett, K., Li, S., McCormack, E., Gjertsen, B. T., Micklem, D. R., Akslen, L. A., Glackin, C., & Lorens, J. B. (2010). Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proceedings of the National Academy of Sciences of the United States of America, 107, 1124–1129.PubMedCentralPubMed
133.
Vajkoczy, P., Knyazev, P., Kunkel, A., Capelle, H. H., Behrndt, S., von Tengg-Kobligk, H., Kiessling, F., Eichelsbacher, U., Essig, M., Read, T. A., Erber, R., & Ullrich, A. (2006). Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proceedings of the National Academy of Sciences of the United States of America, 103, 5799–5804.PubMedCentralPubMed
134.
Hector, A., Montgomery, E. A., Karikari, C., Canto, M., Dunbar, K. B., Wang, J. S., Feldmann, G., Hong, S. M., Haffner, M. C., Meeker, A. K., Holland, S. J., Yu, J., Heckrodt, T. J., Zhang, J., Ding, P., Goff, D., Singh, R., Roa, J. C., Marimuthu, A., Riggins, G. J., Eshleman, J. R., Nelkin, B. D., Pandey, A., & Maitra, A. (2010). The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biology & Therapy, 10, 1009–1018.
135.
Koorstra, J. B., Karikari, C. A., Feldmann, G., Bisht, S., Rojas, P. L., Offerhaus, G. J., Alvarez, H., & Maitra, A. (2009). The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biology & Therapy, 8, 618–626.
136.
Gustafsson, A., Martuszewska, D., Johansson, M., Ekman, C., Hafizi, S., Ljungberg, B., & Dahlback, B. (2009). Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clinical Cancer Research, 15, 4742–4749.PubMed
137.
Zhang, Y. X., Knyazev, P. G., Cheburkin, Y. V., Sharma, K., Knyazev, Y. P., Orfi, L., Szabadkai, I., Daub, H., Keri, G., & Ullrich, A. (2008). AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Research, 68, 1905–1915.PubMed
138.
Hutterer, M., Knyazev, P., Abate, A., Reschke, M., Maier, H., Stefanova, N., Knyazeva, T., Barbieri, V., Reindl, M., Muigg, A., Kostron, H., Stockhammer, G., & Ullrich, A. (2008). Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clinical Cancer Research, 14, 130–138.PubMed
139.
Mishra, A., Wang, J., Shiozawa, Y., McGee, S., Kim, J., Jung, Y., Joseph, J., Berry, J. E., Havens, A., Pienta, K. J., & Taichman, R. S. (2012). Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer. Molecular Cancer Research, 10, 703–712.PubMedCentralPubMed
140.
Kalluri, R., & Zeisberg, M. (2006). Fibroblasts in cancer. Nature Reviews Cancer, 6, 392–401.PubMed
141.
Liotta, L. A., & Kohn, E. C. (2001). The microenvironment of the tumour–host interface. Nature, 411, 375–379.PubMed
142.
Chung, L. W., Baseman, A., Assikis, V., & Zhau, H. E. (2005). Molecular insights into prostate cancer progression: The missing link of tumor microenvironment. The Journal of Urology, 173, 10–20.PubMed
143.
Kaminski, A., Hahne, J. C., Haddouti el, M., Florin, A., Wellmann, A., & Wernert, N. (2006). Tumour–stroma interactions between metastatic prostate cancer cells and fibroblasts. International Journal of Molecular Medicine, 18, 941–950.PubMed
144.
Giannoni, E., Bianchini, F., Calorini, L., & Chiarugi, P. (2011). Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness. Antioxidants & Redox Signaling, 14, 2361–2371.
145.
Lafon, C., Mathieu, C., Guerrin, M., Pierre, O., Vidal, S., & Valette, A. (1996). Transforming growth factor beta 1-induced apoptosis in human ovarian carcinoma cells: protection by the antioxidant N-acetylcysteine and bcl-2. Cell Growth & Differentiation, 7, 1095–1104.
146.
Rhyu, D. Y., Yang, Y., Ha, H., Lee, G. T., Song, J. S., Uh, S. T., & Lee, H. B. (2005). Role of reactive oxygen species in TGF-beta1-induced mitogen-activated protein kinase activation and epithelial–mesenchymal transition in renal tubular epithelial cells. Journal of the American Society of Nephrology, 16, 667–675.PubMed
147.
Radisky, D. C., Levy, D. D., Littlepage, L. E., Liu, H., Nelson, C. M., Fata, J. E., Leake, D., Godden, E. L., Albertson, D. G., Nieto, M. A., Werb, Z., & Bissell, M. J. (2005). Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature, 436, 123–127.PubMedCentralPubMed
148.
Barnett, P., Arnold, R. S., Mezencev, R., Chung, L. W., Zayzafoon, M., & Odero-Marah, V. (2011). Snail-mediated regulation of reactive oxygen species in ARCaP human prostate cancer cells. Biochemical and Biophysical Research Communications, 404, 34–39.PubMedCentralPubMed
149.
Das, T. P., Suman, S., & Damodaran, C. (2013). Reactive oxygen species generation inhibits epithelial–mesenchymal transition and promotes growth arrest in prostate cancer cells. Molecular Carcinogenesis. doi:10.​1002/​mc.​22014.
150.
Sun, Y., Campisi, J., Higano, C., Beer, T. M., Porter, P., Coleman, I., True, L., & Nelson, P. S. (2012). Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nature Medicine, 18, 1359–1368.PubMedCentralPubMed
151.
Zhang, Y., Daquinag, A., Traktuev, D. O., Amaya-Manzanares, F., Simmons, P. J., March, K. L., Pasqualini, R., Arap, W., & Kolonin, M. G. (2009). White adipose tissue cells are recruited by experimental tumors and promote cancer progression in mouse models. Cancer Research, 69, 5259–5266.PubMed
152.
Chao, Y., Wu, Q., Shepard, C., & Wells, A. (2012). Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance. Clinical & Experimental Metastasis, 29, 39–50.
153.
Yates, C. C., Shepard, C. R., Stolz, D. B., & Wells, A. (2007). Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. British Journal of Cancer, 96, 1246–1252.PubMedCentralPubMed
154.
S. Josson, S. Sharp, S. Y. Sung, P. A. Johnstone, R. Aneja, R. Wang, M. Gururajan, T. Turner, L. W. Chung, and C. Yates (2010) Tumor–stromal interactions influence radiation sensitivity in epithelial- versus mesenchymal-like prostate cancer cells. Journal of Oncology, 2010. doi:10.​1155/​2010/​232831.
155.
Oltean, S., Sorg, B. S., Albrecht, T., Bonano, V. I., Brazas, R. M., Dewhirst, M. W., & Garcia-Blanco, M. A. (2006). Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. Proceedings of the National Academy of Sciences of the United States of America, 103, 14116–14121.PubMedCentralPubMed
156.
Giannini, G., Cabri, W., Fattorusso, C., & Rodriquez, M. (2012). Histone deacetylase inhibitors in the treatment of cancer: Overview and perspectives. Future Medicinal Chemistry, 4, 1439–1460.PubMed
157.
Kong, D., Ahmad, A., Bao, B., Li, Y., Banerjee, S., & Sarkar, F. H. (2012). Histone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells. PLoS One, 7, e45045.PubMedCentralPubMed
158.
Bradley, D., Rathkopf, D., Dunn, R., Stadler, W. M., Liu, G., Smith, D. C., Pili, R., Zwiebel, J., Scher, H., & Hussain, M. (2009). Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: A study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer, 115, 5541–5549.PubMedCentralPubMed
159.
Martinez-Garcia, E., Popovic, R., Min, D. J., Sweet, S. M., Thomas, P. M., Zamdborg, L., Heffner, A., Will, C., Lamy, L., Staudt, L. M., Levens, D. L., Kelleher, N. L., & Licht, J. D. (2011). The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood, 117, 211–220.PubMedCentralPubMed
160.
Hudlebusch, H. R., Skotte, J., Santoni-Rugiu, E., Zimling, Z. G., Lees, M. J., Simon, R., Sauter, G., Rota, R., De Ioris, M. A., Quarto, M., Johansen, J. V., Jorgensen, M., Rechnitzer, C., Maroun, L. L., Schroder, H., Petersen, B. L., & Helin, K. (2011). MMSET is highly expressed and associated with aggressiveness in neuroblastoma. Cancer Research, 71, 4226–4235.PubMed
161.
Kassambara, A., Klein, B., & Moreaux, J. (2009). MMSET is overexpressed in cancers: link with tumor aggressiveness. Biochemical and Biophysical Research Communications, 379, 840–845.PubMed
162.
Ezponda, T., Popovic, R., Shah, M. Y., Martinez-Garcia, E., Zheng, Y., Min, D. J., Will, C., Neri, A., Kelleher, N. L., Yu, J., & Licht, J. D. (2013). The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial–mesenchymal transition and invasive properties of prostate cancer. Oncogene, 32, 2882–2890.PubMedCentralPubMed
163.
Smith, J. (2002). Human Sir2 and the “silencing” of p53 activity. Trends in Cell Biology, 12, 404–406.PubMed
164.
Giannakou, M. E., & Partridge, L. (2004). The interaction between FOXO and SIRT1: Tipping the balance towards survival. Trends in Cell Biology, 14, 408–412.PubMed
165.
Byles, V., Zhu, L., Lovaas, J. D., Chmilewski, L. K., Wang, J., Faller, D. V., & Dai, Y. (2012). SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene, 31, 4619–4629.PubMed
166.
Cao, Q., Yu, J., Dhanasekaran, S. M., Kim, J. H., Mani, R. S., Tomlins, S. A., Mehra, R., Laxman, B., Cao, X., Kleer, C. G., Varambally, S., & Chinnaiyan, A. M. (2008). Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene, 27, 7274–7284.PubMedCentralPubMed
167.
Saha, B., Kaur, P., Tsao-Wei, D., Naritoku, W. Y., Groshen, S., Datar, R. H., Jones, L. W., & Imam, S. A. (2008). Unmethylated E-cadherin gene expression is significantly associated with metastatic human prostate cancer cells in bone. Prostate, 68, 1681–1688.PubMed
168.
Jansson, M. D., & Lund, A. H. (2012). MicroRNA and cancer. Molecular Oncology, 6, 590–610.PubMed
169.
Bartel, D. P. (2004). MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell, 116, 281–297.PubMed
170.
Bullock, M. D., Sayan, A. E., Packham, G. K., & Mirnezami, A. H. (2012). MicroRNAs: critical regulators of epithelial to mesenchymal (EMT) and mesenchymal to epithelial transition (MET) in cancer progression. Biology of the Cell, 104, 3–12.PubMed
171.
Liu, Y. N., Yin, J. J., Abou-Kheir, W., Hynes, P. G., Casey, O. M., Fang, L., Yi, M., Stephens, R. M., Seng, V., Sheppard-Tillman, H., Martin, P., & Kelly, K. (2013). MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms. Oncogene, 32, 296–306.PubMed
172.
Kong, D., Li, Y., Wang, Z., Banerjee, S., Ahmad, A., Kim, H. R., & Sarkar, F. H. (2009). miR-200 regulates PDGF-D-mediated epithelial–mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells, 27, 1712–1721.PubMedCentralPubMed
173.
Kong, D., Banerjee, S., Ahmad, A., Li, Y., Wang, Z., Sethi, S., & Sarkar, F. H. (2010). Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One, 5, e12445.PubMedCentralPubMed
174.
Puhr, M., Hoefer, J., Schafer, G., Erb, H. H., Oh, S. J., Klocker, H., Heidegger, I., Neuwirt, H., & Culig, Z. (2012). Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. The American Journal of Pathology, 181, 2188–2201.PubMed
175.
Qu, Y., Li, W. C., Hellem, M. R., Rostad, K., Popa, M., McCormack, E., Oyan, A. M., Kalland, K. H., & Ke, X. S. (2013). MiR-182 and miR-203 induce mesenchymal to epithelial transition and self-sufficiency of growth signals via repressing SNAI2 in prostate cells. International Journal of Cancer, 133, 544–555.
176.
Coppola, V., Musumeci, M., Patrizii, M., Cannistraci, A., Addario, A., Maugeri-Sacca, M., Biffoni, M., Francescangeli, F., Cordenonsi, M., Piccolo, S., Memeo, L., Pagliuca, A., Muto, G., Zeuner, A., De Maria, R., & Bonci, D. (2013). BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial–mesenchymal transition. Oncogene, 32, 1843–1853.PubMed
177.
Watahiki, A., Macfarlane, R. J., Gleave, M. E., Crea, F., Wang, Y., Helgason, C. D., & Chi, K. N. (2013). Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer. International Journal of Molecular Sciences, 14, 7757–7770.PubMedCentralPubMed
178.
Ru, P., Steele, R., Newhall, P., Phillips, N. J., Toth, K., & Ray, R. B. (2012). miRNA-29b suppresses prostate cancer metastasis by regulating epithelial–mesenchymal transition signaling. Molecular Cancer Therapeutics, 11, 1166–1173.PubMed
179.
Tucci, P., Agostini, M., Grespi, F., Markert, E. K., Terrinoni, A., Vousden, K. H., Muller, P. A., Dotsch, V., Kehrloesser, S., Sayan, B. S., Giaccone, G., Lowe, S. W., Takahashi, N., Vandenabeele, P., Knight, R. A., Levine, A. J., & Melino, G. (2012). Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 109, 15312–15317.PubMedCentralPubMed
180.
Zi, X., & Agarwal, R. (1999). Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: Implications for prostate cancer intervention. Proceedings of the National Academy of Sciences of the United States of America, 96, 7490–7495.PubMedCentralPubMed
181.
Tyagi, A. K., Singh, R. P., Agarwal, C., Chan, D. C., & Agarwal, R. (2002). Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis. Clinical Cancer Research, 8, 3512–3519.PubMed
182.
Dhanalakshmi, S., Agarwal, P., Glode, L. M., & Agarwal, R. (2003). Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and apoptotic death. International Journal of Cancer, 106, 699–705.
183.
Flaig, T. W., Su, L. J., Harrison, G., Agarwal, R., & Glode, L. M. (2007). Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells. International Journal of Cancer, 120, 2028–2033.
184.
Tyagi, A., Bhatia, N., Condon, M. S., Bosland, M. C., Agarwal, C., & Agarwal, R. (2002). Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells. Prostate, 53, 211–217.PubMed
185.
Agarwal, C., Tyagi, A., Kaur, M., & Agarwal, R. (2007). Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. Carcinogenesis, 28, 1463–1470.PubMed
186.
Zhu, W., Zhang, J. S., & Young, C. Y. (2001). Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP. Carcinogenesis, 22, 1399–1403.PubMed
187.
Mokhtari, M. J., Motamed, N., & Shokrgozar, M. A. (2008). Evaluation of silibinin on the viability, migration and adhesion of the human prostate adenocarcinoma (PC-3) cell line. Cell Biology International, 32, 888–892.PubMed
188.
Wu, K. J., Zeng, J., Zhu, G. D., Zhang, L. L., Zhang, D., Li, L., Fan, J. H., Wang, X. Y., & He, D. L. (2009). Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression. Acta Pharmacologica Sinica, 30, 1162–1168.PubMed
189.
Wu, K., Zeng, J., Li, L., Fan, J., Zhang, D., Xue, Y., Zhu, G., Yang, L., Wang, X., & He, D. (2010). Silibinin reverses epithelial-to-mesenchymal transition in metastatic prostate cancer cells by targeting transcription factors. Oncology Reports, 23, 1545–1552.PubMed
190.
Jung, H. J., Park, J. W., Lee, J. S., Lee, S. R., Jang, B. C., Suh, S. I., Suh, M. H., & Baek, W. K. (2009). Silibinin inhibits expression of HIF-1alpha through suppression of protein translation in prostate cancer cells. Biochemical and Biophysical Research Communications, 390, 71–76.PubMed
191.
Zhang, L. L., Li, L., Wu, D. P., Fan, J. H., Li, X., Wu, K. J., Wang, X. Y., & He, D. L. (2008). A novel anti-cancer effect of genistein: reversal of epithelial mesenchymal transition in prostate cancer cells. Acta Pharmacologica Sinica, 29, 1060–1068.PubMed
192.
Zhang, L., Li, L., Jiao, M., Wu, D., Wu, K., Li, X., Zhu, G., Yang, L., Wang, X., Hsieh, J. T., & He, D. (2012). Genistein inhibits the stemness properties of prostate cancer cells through targeting Hedgehog-Gli1 pathway. Cancer Letters, 323, 48–57.PubMed
193.
Chiyomaru, T., Yamamura, S., Fukuhara, S., Hidaka, H., Majid, S., Saini, S., Arora, S., Deng, G., Shahryari, V., Chang, I., Tanaka, Y., Tabatabai, Z. L., Enokida, H., Seki, N., Nakagawa, M., & Dahiya, R. (2013). Genistein up-regulates tumor suppressor microRNA-574-3p in prostate cancer. PLoS One, 8, e58929.PubMedCentralPubMed
194.
Baritaki, S., Chapman, A., Yeung, K., Spandidos, D. A., Palladino, M., & Bonavida, B. (2009). Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction. Oncogene, 28, 3573–3585.PubMed
195.
Morel, A. P., Lievre, M., Thomas, C., Hinkal, G., Ansieau, S., & Puisieux, A. (2008). Generation of breast cancer stem cells through epithelial–mesenchymal transition. PLoS One, 3, e2888.PubMedCentralPubMed
196.
Lan, L., Luo, Y., Cui, D., Shi, B. Y., Deng, W., Huo, L. L., Chen, H. L., Zhang, G. Y., & Deng, L. L. (2013). Epithelial–mesenchymal transition triggers cancer stem cell generation in human thyroid cancer cells. International Journal of Oncology, 43, 113–120.PubMed
197.
Klarmann, G. J., Hurt, E. M., Mathews, L. A., Zhang, X., Duhagon, M. A., Mistree, T., Thomas, S. B., & Farrar, W. L. (2009). Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clinical & Experimental Metastasis, 26, 433–446.
198.
Albino, D., Longoni, N., Curti, L., Mello-Grand, M., Pinton, S., Civenni, G., Thalmann, G., D’Ambrosio, G., Sarti, M., Sessa, F., Chiorino, G., Catapano, C. V., & Carbone, G. M. (2012). ESE3/EHF controls epithelial cell differentiation and its loss leads to prostate tumors with mesenchymal and stem-like features. Cancer Research, 72, 2889–2900.PubMed
199.
Lukacs, R. U., Memarzadeh, S., Wu, H., & Witte, O. N. (2010). Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell, 7, 682–693.PubMedCentralPubMed
200.
Domingo-Domenech, J., Vidal, S. J., Rodriguez-Bravo, V., Castillo-Martin, M., Quinn, S. A., Rodriguez-Barrueco, R., Bonal, D. M., Charytonowicz, E., Gladoun, N., de la Iglesia-Vicente, J., Petrylak, D. P., Benson, M. C., Silva, J. M., & Cordon-Cardo, C. (2012). Suppression of acquired docetaxel resistance in prostate cancer through depletion of Notch- and Hedgehog-dependent tumor-initiating cells. Cancer Cell, 22, 373–388.PubMed
201.
Bae, K. M., Su, Z., Frye, C., McClellan, S., Allan, R. W., Andrejewski, J. T., Kelley, V., Jorgensen, M., Steindler, D. A., Vieweg, J., & Siemann, D. W. (2010). Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. The Journal of Urology, 183, 2045–2053.PubMed
202.
Yan, H., Chen, X., Zhang, Q., Qin, J., Li, H., Liu, C., Calhoun-Davis, T., Coletta, L. D., Klostergaard, J., Fokt, I., Skora, S., Priebe, W., Bi, Y., & Tang, D. G. (2011). Drug-tolerant cancer cells show reduced tumor-initiating capacity: Depletion of CD44 cells and evidence for epigenetic mechanisms. PLoS One, 6, e24397.PubMedCentralPubMed
203.
Wang, Z. A., & Shen, M. M. (2011). Revisiting the concept of cancer stem cells in prostate cancer. Oncogene, 30, 1261–1271.PubMed
204.
Gupta, P. B., Onder, T. T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R. A., & Lander, E. S. (2009). Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell, 138, 645–659.PubMed
205.
Allard, W. J., Matera, J., Miller, M. C., Repollet, M., Connelly, M. C., Rao, C., Tibbe, A. G., Uhr, J. W., & Terstappen, L. W. (2004). Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clinical Cancer Research, 10, 6897–6904.PubMed
206.
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W., & Hayes, D. F. (2004). Circulating tumor cells, disease progression, and survival in metastatic breast cancer. The New England Journal of Medicine, 351, 781–791.PubMed
207.
de Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W., Pienta, K. J., & Raghavan, D. (2008). Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clinical Cancer Research, 14, 6302–6309.PubMed
208.
Cohen, S. J., Punt, C. J., Iannotti, N., Saidman, B. H., Sabbath, K. D., Gabrail, N. Y., Picus, J., Morse, M., Mitchell, E., Miller, M. C., Doyle, G. V., Tissing, H., Terstappen, L. W., & Meropol, N. J. (2008). Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 26, 3213–3221.PubMed
209.
Khan, M. S., Kirkwood, A., Tsigani, T., Garcia-Hernandez, J., Hartley, J. A., Caplin, M. E., & Meyer, T. (2013). Circulating tumor cells as prognostic markers in neuroendocrine tumors. Journal of Clinical Oncology, 31, 365–372.PubMed
210.
Scher, H. I., Morris, M. J., Basch, E., & Heller, G. (2011). End points and outcomes in castration-resistant prostate cancer: From clinical trials to clinical practice. Journal of Clinical Oncology, 29, 3695–3704.PubMedCentralPubMed
211.
Lecharpentier, A., Vielh, P., Perez-Moreno, P., Planchard, D., Soria, J. C., & Farace, F. (2011). Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. British Journal of Cancer, 105, 1338–1341.PubMedCentralPubMed
212.
Krebs, M. G., Hou, J. M., Sloane, R., Lancashire, L., Priest, L., Nonaka, D., Ward, T. H., Backen, A., Clack, G., Hughes, A., Ranson, M., Blackhall, F. H., & Dive, C. (2012). Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. Journal of Thoracic Oncology, 7, 306–315.PubMed
213.
Bellizzi, A., Sebastian, S., Ceglia, P., Centonze, M., Divella, R., Manzillo, E. F., Azzariti, A., Silvestris, N., Montemurro, S., Caliandro, C., De Luca, R., Cicero, G., Rizzo, S., Russo, A., Quaranta, M., Simone, G., & Paradiso, A. (2013). Co-expression of CD133(+)/CD44(+) in human colon cancer and liver metastasis. Journal of Cellular Physiology, 228, 408–415.PubMed
214.
Barriere, G., Riouallon, A., Renaudie, J., Tartary, M., & Rigaud, M. (2012). Mesenchymal and stemness circulating tumor cells in early breast cancer diagnosis. BMC Cancer, 12, 114.PubMedCentralPubMed
215.
Sieuwerts, A. M., Kraan, J., Bolt, J., van der Spoel, P., Elstrodt, F., Schutte, M., Martens, J. W., Gratama, J. W., Sleijfer, S., & Foekens, J. A. (2009). Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. Journal of the National Cancer Institute, 101, 61–66.PubMedCentralPubMed
216.
Raimondi, C., Gradilone, A., Naso, G., Vincenzi, B., Petracca, A., Nicolazzo, C., Palazzo, A., Saltarelli, R., Spremberg, F., Cortesi, E., & Gazzaniga, P. (2011). Epithelial–mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Research and Treatment, 130, 449–455.PubMed
217.
Ozkumur, E., Shah, A. M., Ciciliano, J. C., Emmink, B. L., Miyamoto, D. T., Brachtel, E., Yu, M., Chen, P. I., Morgan, B., Trautwein, J., Kimura, A., Sengupta, S., Stott, S. L., Karabacak, N. M., Barber, T. A., Walsh, J. R., Smith, K., Spuhler, P. S., Sullivan, J. P., Lee, R. J., Ting, D. T., Luo, X., Shaw, A. T., Bardia, A., Sequist, L. V., Louis, D. N., Maheswaran, S., Kapur, R., Haber, D. A., & Toner, M. (2013). “Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells,”. Science Translational Medicine, 5, 179ra47.PubMedCentralPubMed
218.
Ryan, C. J., Shah, S., Efstathiou, E., Smith, M. R., Taplin, M. E., Bubley, G. J., Logothetis, C. J., Kheoh, T., Kilian, C., Haqq, C. M., Molina, A., & Small, E. J. (2011). Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clinical Cancer Research, 17, 4854–4861.PubMedCentralPubMed
219.
Smith, D. C., Smith, M. R., Sweeney, C., Elfiky, A. A., Logothetis, C., Corn, P. G., Vogelzang, N. J., Small, E. J., Harzstark, A. L., Gordon, M. S., Vaishampayan, U. N., Haas, N. B., Spira, A. I., Lara, P. N., Jr., Lin, C. C., Srinivas, S., Sella, A., Schoffski, P., Scheffold, C., Weitzman, A. L., & Hussain, M. (2013). Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trial. Journal of Clinical Oncology, 31, 412–419.PubMed
220.
R. J. Lee, P. J. Saylor, M. D. Michaelson, S. M. Rothenberg, M. E. Smas, D. T. Miyamoto, C. A. Gurski, W. Xie, S. Maheswaran, D. A. Haber, J. G. Goldin, and M. R. Smith, “A Dose-Ranging Study of Cabozantinib in Men with Castration-Resistant Prostate Cancer and Bone Metastases,” Clin Cancer Res, May 15 2013
221.
Kwok, W. K., Ling, M. T., Lee, T. W., Lau, T. C., Zhou, C., Zhang, X., Chua, C. W., Chan, K. W., Chan, F. L., Glackin, C., Wong, Y. C., & Wang, X. (2005). Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Research, 65, 5153–5162.PubMed
222.
Sethi, S., Macoska, J., Chen, W., & Sarkar, F. H. (2010). Molecular signature of epithelial–mesenchymal transition (EMT) in human prostate cancer bone metastasis. American Journal of Translational Research, 3, 90–99.PubMedCentralPubMed
223.
Gravdal, K., Halvorsen, O. J., Haukaas, S. A., & Akslen, L. A. (2007). A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clinical Cancer Research, 13, 7003–7011.PubMed
224.
Behnsawy, H. M., Miyake, H., Harada, K., & Fujisawa, M. (2013). Expression patterns of epithelial–mesenchymal transition markers in localized prostate cancer: Significance in clinicopathological outcomes following radical prostatectomy. BJU International, 111, 30–37.PubMed
225.
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X. W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., Lee, C., Montie, J. E., Shah, R. B., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M. (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science, 310, 644–648.PubMed
226.
Tomlins, S. A., Laxman, B., Dhanasekaran, S. M., Helgeson, B. E., Cao, X., Morris, D. S., Menon, A., Jing, X., Cao, Q., Han, B., Yu, J., Wang, L., Montie, J. E., Rubin, M. A., Pienta, K. J., Roulston, D., Shah, R. B., Varambally, S., Mehra, R., & Chinnaiyan, A. M. (2007). Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature, 448, 595–599.PubMed
227.
Gupta, S., Iljin, K., Sara, H., Mpindi, J. P., Mirtti, T., Vainio, P., Rantala, J., Alanen, K., Nees, M., & Kallioniemi, O. (2010). FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Research, 70, 6735–6745.PubMed
228.
Leshem, O., Madar, S., Kogan-Sakin, I., Kamer, I., Goldstein, I., Brosh, R., Cohen, Y., Jacob-Hirsch, J., Ehrlich, M., Ben-Sasson, S., Goldfinger, N., Loewenthal, R., Gazit, E., Rotter, V., & Berger, R. (2011). TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS One, 6, e21650.PubMedCentralPubMed
229.
Demichelis, F., Fall, K., Perner, S., Andren, O., Schmidt, F., Setlur, S. R., Hoshida, Y., Mosquera, J. M., Pawitan, Y., Lee, C., Adami, H. O., Mucci, L. A., Kantoff, P. W., Andersson, S. O., Chinnaiyan, A. M., Johansson, J. E., & Rubin, M. A. (2007). TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene, 26, 4596–4599.PubMed
230.
Nam, R. K., Sugar, L., Yang, W., Srivastava, S., Klotz, L. H., Yang, L. Y., Stanimirovic, A., Encioiu, E., Neill, M., Loblaw, D. A., Trachtenberg, J., Narod, S. A., & Seth, A. (2007). Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. British Journal of Cancer, 97, 1690–1695.PubMedCentralPubMed
231.
Attard, G., Clark, J., Ambroisine, L., Fisher, G., Kovacs, G., Flohr, P., Berney, D., Foster, C. S., Fletcher, A., Gerald, W. L., Moller, H., Reuter, V., De Bono, J. S., Scardino, P., Cuzick, J., & Cooper, C. S. (2008). Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene, 27, 253–263.PubMedCentralPubMed
232.
Pettersson, A., Graff, R. E., Bauer, S. R., Pitt, M. J., Lis, R. T., Stack, E. C., Martin, N. E., Kunz, L., Penney, K. L., Ligon, A. H., Suppan, C., Flavin, R., Sesso, H. D., Rider, J. R., Sweeney, C., Stampfer, M. J., Fiorentino, M., Kantoff, P. W., Sanda, M. G., Giovannucci, E. L., Ding, E. L., Loda, M., & Mucci, L. A. (2012). The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: A cohort study and meta-analysis. Cancer Epidemiology, Biomarkers & Prevention, 21, 1497–1509.
233.
Chen, C. L., Mahalingam, D., Osmulski, P., Jadhav, R. R., Wang, C. M., Leach, R. J., Chang, T. C., Weitman, S. D., Kumar, A. P., Sun, L., Gaczynska, M. E., Thompson, I. M., & Huang, T. H. (2013). Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer. Prostate, 73, 813–826.PubMed
234.
Jennbacken, K., Tesan, T., Wang, W., Gustavsson, H., Damber, J. E., & Welen, K. (2010). N-Cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer. Endocrine-Related Cancer, 17, 469–479.PubMed
235.
Tanaka, H., Kono, E., Tran, C. P., Miyazaki, H., Yamashiro, J., Shimomura, T., Fazli, L., Wada, R., Huang, J., Vessella, R. L., An, J., Horvath, S., Gleave, M., Rettig, M. B., Wainberg, Z. A., & Reiter, R. E. (2010). Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nature Medicine, 16, 1414–1420.PubMedCentralPubMed
236.
Putzke, A. P., Ventura, A. P., Bailey, A. M., Akture, C., Opoku-Ansah, J., Celiktas, M., Hwang, M. S., Darling, D. S., Coleman, I. M., Nelson, P. S., Nguyen, H. M., Corey, E., Tewari, M., Morrissey, C., Vessella, R. L., & Knudsen, B. S. (2011). Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases. The American Journal of Pathology, 179, 400–410.PubMedCentralPubMed
237.
Giampieri, S., Manning, C., Hooper, S., Jones, L., Hill, C. S., & Sahai, E. (2009). Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nature Cell Biology, 11, 1287–1296.PubMedCentralPubMed
238.
Armstrong, A. J., Tannock, I. F., de Wit, R., George, D. J., Eisenberger, M., & Halabi, S. (2010). The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. European Journal of Cancer, 46, 517–525.PubMed
239.
Qin, J., Liu, X., Laffin, B., Chen, X., Choy, G., Jeter, C. R., Calhoun-Davis, T., Li, H., Palapattu, G. S., Pang, S., Lin, K., Huang, J., Ivanov, I., Li, W., Suraneni, M. V., & Tang, D. G. (2012). The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell, 10, 556–569.PubMedCentralPubMed
240.
Kottke, T., Errington, F., Pulido, J., Galivo, F., Thompson, J., Wongthida, P., Diaz, R. M., Chong, H., Ilett, E., Chester, J., Pandha, H., Harrington, K., Selby, P., Melcher, A., & Vile, R. (2011). Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nature Medicine, 17, 854–859.PubMedCentralPubMed
241.
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., Xu, Y., Frohlich, M. W., & Schellhammer, P. F. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. The New England Journal of Medicine, 363, 411–422.PubMed
242.
Kantoff, P. W., Schuetz, T. J., Blumenstein, B. A., Glode, L. M., Bilhartz, D. L., Wyand, M., Manson, K., Panicali, D. L., Laus, R., Schlom, J., Dahut, W. L., Arlen, P. M., Gulley, J. L., & Godfrey, W. R. (2010). Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, 28, 1099–1105.PubMedCentralPubMed
243.
Yuan, T. C., Veeramani, S., & Lin, M. F. (2007). Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocrine-Related Cancer, 14, 531–547.PubMed
244.
Carver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V. K., Le, C., Koutcher, J., Scher, H., Scardino, P. T., Rosen, N., & Sawyers, C. L. (2011). Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell, 19, 575–586.PubMedCentralPubMed
245.
Bitting, R. L., & Armstrong, A. J. (2013). Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocrine-Related Cancer, 20, R83–R99.PubMed
246.
Glickman, M. S., & Sawyers, C. L. (2012). Converting cancer therapies into cures: lessons from infectious diseases. Cell, 148, 1089–1098.PubMedCentralPubMed
247.
Goldstein, A. S., Huang, J., Guo, C., Garraway, I. P., & Witte, O. N. (2010). Identification of a cell of origin for human prostate cancer. Science, 329, 568–571.PubMedCentralPubMed
248.
Cottard, F., Asmane, I., Erdmann, E., Bergerat, J. P., Kurtz, J. E., & Ceraline, J. (2013). Constitutively active androgen receptor variants upregulate expression of mesenchymal markers in prostate cancer cells. PLoS One, 8, p. e63466.
249.
Brennen, W. N., Rosen, D. M., Wang, H., Isaacs, J. T., & Denmeade, S. R. (2012). Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. Journal of the National Cancer Institute, 104, 1320–1334.PubMedCentralPubMed
250.
Li, Y., Maitah, M. Y., Ahmad, A., Kong, D., Bao, B., & Sarkar, F. H. (2012). Targeting the Hedgehog signaling pathway for cancer therapy. Expert Opinion on Therapeutic Targets, 16, 49–66.
251.
Groth, C., & Fortini, M. E. (2012). Therapeutic approaches to modulating Notch signaling: Current challenges and future prospects. Seminars in Cell & Developmental Biology, 23, 465–472.
252.
Smith, A. L., Robin, T. P., & Ford, H. L. (2012). Molecular pathways: Targeting the TGF-beta pathway for cancer therapy. Clinical Cancer Research, 18, 4514–4521.PubMed
253.
Liu, G., Sprenger, C., Sun, S., Epilepsia, K. S., Haugk, K., Zhang, X., et al. (2013). AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer. Neoplasia, 15, pp. 1009–1017.
254.
Bitting, R. L., & Armstrong, A. J. (2013). Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer. Cancer Journal, 19, 25–33.
255.
Othus, M., Barlogie, B., Leblanc, M. L., & Crowley, J. J. (2012). Cure models as a useful statistical tool for analyzing survival. Clinical Cancer Research, 18, 3731–3736.PubMedCentralPubMed
256.
Scher, H. I., Fizazi, K., Saad, F., Taplin, M. E., Sternberg, C. N., Miller, K., et al. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England Journal of Medicine, 367, 1187–1197.
257.
Clegg, N. J., Wongvipat, J., Joseph, J. D., Tran, C., Ouk, S., Dilhas, A., Chen, Y., Grillot, K., Bischoff, E. D., Cai, L., Aparicio, A., Dorow, S., Arora, V., Shao, G., Qian, J., Zhao, H., Yang, G., Cao, C., Sensintaffar, J., Wasielewska, T., Herbert, M. R., Bonnefous, C., Darimont, B., Scher, H. I., Smith-Jones, P., Klang, M., Smith, N. D., De Stanchina, E., Wu, N., Ouerfelli, O., Rix, P. J., Heyman, R. A., Jung, M. E., Sawyers, C. L., & Hager, J. H. (2012). ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Research, 72, 1494–1503.PubMedCentralPubMed
258.
Montgomery, R. B., Eisenberger, M. A., Rettig, M., Chu, F., Pili, R., Stephenson, J., Vogelzang, N. J., Morrison, J., & Taplin, M. (2012). Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer. Journal of Clinical Oncology, 30, abstr 4665.
259.
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Jr., Saad, F., Staffurth, J. N., Mainwaring, P., Harland, S., Flaig, T. W., Hutson, T. E., Cheng, T., Patterson, H., Hainsworth, J. D., Ryan, C. J., Sternberg, C. N., Ellard, S. L., Flechon, A., Saleh, M., Scholz, M., Efstathiou, E., Zivi, A., Bianchini, D., Loriot, Y., Chieffo, N., Kheoh, T., Haqq, C. M., & Scher, H. I. (2011). Abiraterone and increased survival in metastatic prostate cancer. The New England Journal of Medicine, 364, 1995–2005.PubMedCentralPubMed
260.
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., Carles, J., Mulders, P. F., Basch, E., Small, E. J., Saad, F., Schrijvers, D., Van Poppel, H., Mukherjee, S. D., Suttmann, H., Gerritsen, W. R., Flaig, T. W., George, D. J., Yu, E. Y., Efstathiou, E., Pantuck, A., Winquist, E., Higano, C. S., Taplin, M. E., Park, Y., Kheoh, T., Griffin, T., Scher, H. I., & Rathkopf, D. E. (2013). Abiraterone in metastatic prostate cancer without previous chemotherapy. The New England Journal of Medicine, 368, 138–148.PubMedCentralPubMed
261.
Kaku, T., Hitaka, T., Ojida, A., Matsunaga, N., Adachi, M., Tanaka, T., Hara, T., Yamaoka, M., Kusaka, M., Okuda, T., Asahi, S., Furuya, S., & Tasaka, A. (2011). Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorganic & Medicinal Chemistry, 19, 6383–6399.
262.
Yarom, N., Stewart, D., Malik, R., Wells, J., Avruch, L., & Jonker, D. J. (2013). Phase I clinical trial of Exherin (ADH-1) in patients with advanced solid tumors. Current Clinical Pharmacology, 8, 81–88.PubMed
263.
Austin, P., Freeman, S. A., Gray, C. A., Gold, M. R., Vogl, A. W., Andersen, R. J., Roberge, M., & Roskelley, C. D. (2013). The invasion inhibitor sarasinoside A1 reverses mesenchymal tumor transformation in an e-cadherin-independent manner. Molecular Cancer Research, 11, 530–540.PubMed
264.
Feng, S., Shao, L., Yu, W., Gavine, P., & Ittmann, M. (2012). Targeting fibroblast growth factor receptor signaling inhibits prostate cancer progression. Clinical Cancer Research, 18, 3880–3888.PubMed
Metadaten
Titel
The role of epithelial plasticity in prostate cancer dissemination and treatment resistance
verfasst von
Rhonda L. Bitting
Daneen Schaeffer
Jason A. Somarelli
Mariano A. Garcia-Blanco
Andrew J. Armstrong
Publikationsdatum
01.09.2014
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 2-3/2014
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-013-9483-z

Weitere Artikel der Ausgabe 2-3/2014

Cancer and Metastasis Reviews 2-3/2014 Zur Ausgabe

NON-THEMATIC REVIEW

Immune regulation of therapy-resistant niches: emerging targets for improving anticancer drug responses

OriginalPaper

Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy

OriginalPaper

Mouse models of prostate cancer: picking the best model for the question

OriginalPaper

Recent progress on nutraceutical research in prostate cancer

OriginalPaper

Novel drugs targeting the androgen receptor pathway in prostate cancer

OriginalPaper

Emerging technology: applications of Raman spectroscopy for prostate cancer

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

ICI-Therapie in der Schwangerschaft wird gut toleriert

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Krebspatienten impfen: Was? Wen? Und wann nicht?

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Müde im Alter? Auch an die Nebenniere denken

22.04.2024 | Prostatakarzinom | Nachrichten

Stufenschema weist Prostatakarzinom zuverlässig nach
weitere anzeigen

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen